Summit Therapeutics

Summit Therapeutics EBITDA per Share

The EBITDA per Share of Summit Therapeutics (SMMT) as of Nov 22, 2026 is -0.29 USD. In the previous year, EBITDA per Share was -0.14 USD — a change of 105.05% (lower).

EBITDA per Share

-0.29USD

YoY

105.05%

Last updated:

EBITDA per Share of Summit Therapeutics is 2024 -0.29 USD. EBITDA per Share of Summit Therapeutics was 2023 -0.14 USD. It decreases by 105.05% lower compared to the previous year.

The Summit Therapeutics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
-2.12 USD
Jan 1, 2018
0.72 USD
Jan 1, 2019
-0.81 USD
Jan 1, 2020
-0.73 USD
Jan 1, 2021
-0.92 USD
Jan 1, 2022
-0.32 USD
Jan 1, 2023
-0.14 USD
Jan 1, 2024
-0.29 USD
The Summit Therapeutics EBITDA per Share history
YEAREBITDA per ShareYoY
-0.29USD+105.05%
-0.14USD-55.85%
-0.32USD-64.87%
-0.92USD+25.79%
-0.73USD-8.96%
-0.81USD-212.12%
0.72USD-133.90%
-2.12USD+438.24%
-0.39USD+11.99%
-0.35USD+9.14%
-0.32USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Summit Therapeutics Stock analysis

What does Summit Therapeutics do? Summit Therapeutics Inc. is a global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines for the treatment of life-threatening and rare diseases. The company is headquartered in Massachusetts, USA and also has offices in Oxford, UK. Summit Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Summit Therapeutics stock

EBITDA per Share of Summit Therapeutics is -0.29 USD in 2024.

EBITDA per Share of Summit Therapeutics changed from -0.14 USD to -0.29 USD, representing a 105.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Summit Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Summit Therapeutics

All Key Metrics — Summit Therapeutics